Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI Study of Brepocitinib and Oral Contraceptives in Healthy Females
NCT04267250Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brepocitinib in plaque psoriasis, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and 3 more, sponsored by Pfizer. Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time. Started Aug 2020; status: completed.
02
Drugs
brepocitinib
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)systemic lupus erythematosus (SLE)dermatomyositis (DM)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04267250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267250.